ResearchIn-Press PreviewCell biologyOncology
Open Access | 10.1172/jci.insight.186703
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by Ivanova, A. in: PubMed | Google Scholar
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by Wilson, T. in: PubMed | Google Scholar
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by Ghannad-Zadeh, K. in: PubMed | Google Scholar
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by Tse, E. in: PubMed | Google Scholar
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by Flick, R. in: PubMed | Google Scholar
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by Wu, M. in: PubMed | Google Scholar
1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada
3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America
Find articles by
Das, S.
in:
PubMed
|
Google Scholar
|
Published July 23, 2025 - More info
More than one third of patients with glioblastoma experience tumour progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier that to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma. In vitro treatment of temozolomide-resistant glioblastoma cells with lomitapide resulted in decreased intracellular ubiquinone levels and sensitized cells to temozolomide-induced ferroptosis. Concomitant treatment with lomitapide and temozolomide (TMZ) prolonged survival and delayed tumour recurrence in a mouse glioblastoma model, compared to treatment with TMZ alone. Our data identified lomitapide as a potential adjunct for treatment of temozolomide-resistant glioblastoma.